Tracking The Evolution Of CDMO Selection Criteria For Biologic Drug Substance Manufacturing

By Jenn Holloway

Year-over-year variation always exists in the selection criteria respondents prioritize in an outsourced manufacturer. As biologics continue to comprise a growing share of FDA approvals, CDMOs would be wise to understand and address patent holders’ frustrations with drug substance manufacturing activities.

As part of an annual CDMO Benchmarking research survey, respondents were asked to review a list of 28 selection attributes and to identify the one criterion most important to them when choosing a provider for biologic drug substance manufacturing services. This year, survey participants primarily came from large (R&D $1B+) or midsize (R&D $100M - $999M) biopharma companies across North America and Western Europe.

Consider these five metrics—tiered by the most noteworthy trends based on the survey responses—when choosing a provider for biological drug substance manufacturing services.